Neogenomics Stock

Neogenomics EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Neogenomics (NEO) as of Jul 29, 2026 is -22.28. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -15.99 — a change of 39.39% (lower).

EV/EBIT

-22.28

YoY

39.39%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Neogenomics is 2026 -22.28 . EV/EBIT (Enterprise Value to EBIT) of Neogenomics was 2025 -15.99 . It decreases by 39.39% lower compared to the previous year.

The Neogenomics EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
85.72 base
Jan 1, 2020
-174.80 base
Jan 1, 2021
-84.05 base
Jan 1, 2022
-1.46 base
Jan 1, 2023
-3.78 base
Jan 1, 2024
-4.53 base
Jan 1, 2025
-4.58 base
Jan 1, 2026 (e)
-3.00 base
YEARPRICE-TO-EBIT
2026 est -3.00
2025 -4.58
2024 -4.53
2023 -3.78
2022 -1.46
2021 -84.05
2020 -174.80
2019 85.72
2018 24.30
2017 48.50
2016 261.33
2015 -17.00
2014 23.59
2013 12.24
2012 19.10
2011 -30.60
2010 -3.66
2009 -6.46
2008 -21.70
2007 -2.15
2006 293.28
Access this data via the Eulerpool API
Get Free API Key

Neogenomics Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Neogenomics's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Neogenomics's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Neogenomics's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Neogenomics grows earnings faster than its peers.

Neogenomics Stock analysis

What does Neogenomics do? Neogenomics Inc. is a leading company in the field of personalized medicine, based in Fort Myers, Florida. It offers integrated diagnostics and pharmaceutical services for oncology and gene therapy, with a focus on providing accurate diagnosis for cancer patients. Neogenomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neogenomics stock

EV/EBIT (Enterprise Value to EBIT) of Neogenomics is -22.28 in 2026.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Neogenomics

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Neogenomics